Table 1.

Protective efficacy of VLP and single-cycle replicable RVFV vaccines in mice

Reference	Vaccine component		RVFV strain	Mouse strain	Immunization			Peak neutralizing antibody titer	% Protective efficacy^a
	Viral proteins	Viral RNAs			Dosage (number)	Route	Adjuvant
VLP-based
de Boer et al., 2010	Gn/Gc		M35/74	BALB/c	10μg (2)	I.P.	No	1000^b	100
de Boer et al., 2010	Gn/Gc		M35/74	BALB/c	10μg (2)	I.P.	Yes	5000^b	100

Mandell et al., 2010	Gn/Gc, gag		MP-12	BALB/cC	6μg (3)	S.C.	Yes	>640	68
	Gn/Gc						Yes	>640	19
	Gn/Gc, N						Yes	>640	56

Naslund et al., 2009	78/NSm/Gn/Gc, L, N	M-UTR with rLuc ORF	ZH548	C57BL/6	10⁵ particles (3)	I.P.	No	250	50
Naslund et al., 2009	78/NSm/Gn/Gc, L, N	M-UTR with rLuc ORF	ZH548	C57BL/6	10⁶ particles (3)	I.P.	No	>1250	92

Pichlmair et al., 2010	78/NSm/Gn/Gc, L, N	M-UTR with N protein-ORF	ZH548	C57BL/6	10⁶ particles (1)	I.P.	No	NT	100

Single-cycle replicable
Kortekaas et al., 2011	78/NSm/Gn/Gc, L, N	L, S-GFP	35/74	BALB/c	10⁶ TCID₅₀ (1)	S.C	No	NT	60
Kortekaas et al., 2011	78/NSm/Gn/Gc, L, N	L, S-GFP	35/74	BALB/c	10⁶ TCID₅₀ (1)	I.M.	No	NT	100

Oreshkova et al., 2013	78/NSm/Gn/Gc, L, N	L, S-Gn	35/74	BALB/cAnCrl	5×10⁵ TCID₅₀ (1)	I.M.	No	2500^b	NT
Oreshkova et al., 2013	78/NSm/Gn/Gc, L, N	L, S-GFP	35/74	BALB/cAnCrl	5×10⁵ TCID₅₀ (1)	I.M.	No	BD^b	NT

Dodd et al., 2012	Gn/Gc, L, N	L, S-GFP	ZH501	C57BL/6	10⁴ TCID₅₀ (1)	S.C	No	320	100
Dodd et al., 2012	Gn/Gc, L, N	L, S-GFP (irradiated)	ZH501	C57BL/6	10⁴ TCID₅₀ (1)	S.C	No	40	20

Murakami et al., 2014	78/NSm/Gn/Gc, L, N	L, M with mutation, S-GFP	MP-12	CD-1	10⁵ pfu (1)	I.M.	No	1280 (238^c)	89
Murakami et al., 2014	78/NSm/Gn/Gc, L, N	L, S-GFP	MP-12	CD-1	10⁵ pfu (1)	I.M.	No	160 (38^c)	45

^a:

Percentage of surviving mice

^b:

Estimated titer (read from the graph in the reference)

^c:

Mean titer

NT: not tested

BD: below detection limit